78,653 Shares in Puma Biotechnology, Inc. (NASDAQ:PBYI) Purchased by Mackenzie Financial Corp

Mackenzie Financial Corp bought a new stake in Puma Biotechnology, Inc. (NASDAQ:PBYI - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 78,653 shares of the biopharmaceutical company's stock, valued at approximately $240,000. Mackenzie Financial Corp owned about 0.16% of Puma Biotechnology as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. SG Americas Securities LLC increased its holdings in Puma Biotechnology by 83.9% in the 4th quarter. SG Americas Securities LLC now owns 24,668 shares of the biopharmaceutical company's stock valued at $75,000 after buying an additional 11,252 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Puma Biotechnology by 19.5% in the 4th quarter. Bank of New York Mellon Corp now owns 331,853 shares of the biopharmaceutical company's stock worth $1,012,000 after purchasing an additional 54,150 shares during the period. Los Angeles Capital Management LLC lifted its stake in shares of Puma Biotechnology by 16.3% in the 4th quarter. Los Angeles Capital Management LLC now owns 285,679 shares of the biopharmaceutical company's stock valued at $871,000 after purchasing an additional 39,984 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its holdings in Puma Biotechnology by 32.3% in the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 487,368 shares of the biopharmaceutical company's stock worth $1,486,000 after purchasing an additional 118,913 shares during the period. Finally, American Century Companies Inc. raised its stake in Puma Biotechnology by 8.4% during the 4th quarter. American Century Companies Inc. now owns 948,376 shares of the biopharmaceutical company's stock worth $2,893,000 after buying an additional 73,833 shares during the period. 61.29% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. HC Wainwright reissued a "buy" rating and set a $7.00 target price on shares of Puma Biotechnology in a research report on Friday, February 28th. Wall Street Zen upgraded Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 22nd.

Puma Biotechnology Price Performance

Shares of Puma Biotechnology stock opened at $3.65 on Friday. The company's fifty day simple moving average is $3.10 and its two-hundred day simple moving average is $3.09. The firm has a market cap of $181.15 million, a PE ratio of 7.60 and a beta of 1.29. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. Puma Biotechnology, Inc. has a 12-month low of $2.23 and a 12-month high of $4.13.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.